CytoDyn (CYDY) Preferred Dividend Payments (2010 - 2013)
CytoDyn's (CYDY) quarterly Preferred Dividend Payments came in at -$790.0 in Q1 2013, up 98.83% YoY from -$397.33 in Q1 2012, and up 43.57% on a QoQ basis from -$1400.0 in Q3 2012.
CytoDyn (CYDY) Preferred Dividend Payments (2010 - 2013) Analysis & Trends
CytoDyn (CYDY) has 4 years of Preferred Dividend Payments data on file, last reported at -$790.0 in Q1 2013.
- Quarterly Preferred Dividend Payments rose 98.83% year-over-year to -$790.0 in Q1 2013, while the trailing twelve-month figure through May 2013 was -$2190.0 (up 97.68% YoY) and the FY2013 annual result came in at -$2190.0, up 97.53% from the prior year.
- Preferred Dividend Payments climbed to -$790.0 in Q1 2013, from -$1400.0 in the prior quarter.
- In the past five years, Preferred Dividend Payments ranged from a high of -$790.0 in Q1 2013 to a low of -$67293.0 in Q1 2012.
- A 4-year average of -$16580.5 and a median of -$4275.0 in 2010 frame the typical range for Preferred Dividend Payments.
- Annual changes were most pronounced in 2012 — Preferred Dividend Payments sank 1060.22% — and 2013, when it surged 98.83%.
- Tracing CYDY's Preferred Dividend Payments over 4 years: stood at -$2750.0 in 2010, then plunged by 110.91% to -$5800.0 in 2011, then jumped by 75.86% to -$1400.0 in 2012, then soared by 43.57% to -$790.0 in 2013.
- The last three Preferred Dividend Payments figures came in at -$790.0 (Q1 2013), -$1400.0 (Q3 2012), and -$21450.0 (Q2 2012), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2013 | -790.00 |
| Aug 31, 2012 | -1,400.00 |
| May 31, 2012 | -21,450.00 |
| Feb 29, 2012 | -67,293.00 |
| Feb 28, 2011 | -5,800.00 |
| Nov 30, 2010 | -2,750.00 |